The Evolving Era of Novel Therapies in Multiple Myeloma
Release Date: November 15, 2016
Expiration Date: November 15, 2017
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
The evolving role of biological and molecular markers in the diagnosis and prognostication of multiple myeloma supports a more accurate and individualized assessment of a patient's risk-level and subsequent selection of treatment. Through an overview of the myeloma-defining events that comprise the revised ISS, and discussion of the correlation between specific cytogenetic abnormalities and response to treatment, participants will gain greater insight into the application of these diagnostic, prognostic and potentially predictive markers in the treatment of their patients with multiple myeloma.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in evolving novel therapies in multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Summarize the roles of diagnosis, prognosis, and defined metrics for response in treatment identification for patients with multiple myeloma
- Outline the role of biomarkers in identifying the most appropriate treatment for a patient with multiple myeloma
The Evolving Era of Novel Therapies in Multiple Myeloma – Joshua Richter, MD
Instructions for Participation and Credit
This activity is eligible for credit through November 15, 2017. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Joshua Richter, MD
Clinical Assistant Professor at Rutgers
Division of Myeloma
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey
Dr. Joshua Richter received his medical degree from New York Medical College. He completed a multiple myeloma residency at St. Vincent’s Hospital – New York Medical College, and a hematology/oncology fellowship at Yale Cancer Center, Yale University. Dr. Richter is a Clinical Assistant Professor at Rutgers and works in the Division of Myeloma at the John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.
Dr. Richter is board certified in internal medicine, hematology, and medical oncology. He has been published in numerous oncology journals, including Blood, Clinical Immunology, and Leukemia & Lymphoma. Dr. Richter has worked at some of the world’s most prestigious cancer centers and specializes in multiple myeloma at John Theurer Cancer Center which allows the division to further expand its internationally-recognized myeloma clinical and research practice.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-122-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Joshua Richter has received honoraria related to speakers’ bureau activities from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, and Takeda Oncology, and formal advisory activities from Amgen, Celgene, Janssen and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Physician Payments, Sunshine Act
MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology.
©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.